Lantheus
Lantheus is a leading radiopharmaceutical-focused company dedicated to improving patient outcomes through innovation in diagnostics and therapeutics. With a history spanning over 65 years, they develop, manufacture, and commercialize advanced radiodiagnostics and radiotherapeutics, expanding into radiotherapeutics driven by their commitment to innovation, perseverance, and partnerships. Their mission is to find, fight, and follow disease to make a difference in patients' lives.
Industries
Nr. of Employees
large (251-1000)
Lantheus
North Billerica, Massachusetts, United States, North America
Products
Radiodiagnostic PET agents for oncology (prostate and neuroendocrine imaging)
PET imaging agents targeting tumor-specific receptors to detect, stage and monitor oncologic disease, including agents developed for prostate cancer and neuroendocrine tumors.
Radiotherapeutic candidates (targeted radioligand therapies)
Targeted radiotherapeutic agents in development that deliver therapeutic radioisotopes to tumor cells for treatment of solid tumors and other indications.
Precision diagnostic agents for neurology (tau and beta-amyloid PET)
Next-generation PET agents targeting tau and beta-amyloid for earlier detection, staging and monitoring of Alzheimer's disease and other dementias.
Cardiac perfusion and diagnostic agents (SPECT/PET and gas tracers)
Radiopharmaceuticals and radiotracer kits for cardiac imaging and perfusion assessment, including technetium-based kits and other gas or tracer products used in cardiovascular molecular imaging.
Radiodiagnostic PET agents for oncology (prostate and neuroendocrine imaging)
PET imaging agents targeting tumor-specific receptors to detect, stage and monitor oncologic disease, including agents developed for prostate cancer and neuroendocrine tumors.
Radiotherapeutic candidates (targeted radioligand therapies)
Targeted radiotherapeutic agents in development that deliver therapeutic radioisotopes to tumor cells for treatment of solid tumors and other indications.
Precision diagnostic agents for neurology (tau and beta-amyloid PET)
Next-generation PET agents targeting tau and beta-amyloid for earlier detection, staging and monitoring of Alzheimer's disease and other dementias.
Cardiac perfusion and diagnostic agents (SPECT/PET and gas tracers)
Radiopharmaceuticals and radiotracer kits for cardiac imaging and perfusion assessment, including technetium-based kits and other gas or tracer products used in cardiovascular molecular imaging.
Services
Partnerships for biomarker development and digital solutions
Collaborative partnerships with academic and industry groups to develop and provide biomarkers and digital tools to support precision medicine and clinical studies.
Clinical trial collaboration for radiopharmaceutical studies
Support for clinical evaluation of radiodiagnostics and radiotherapeutics, including trial design, operational execution, and clinical validation to inform regulatory filings.
Partnerships for biomarker development and digital solutions
Collaborative partnerships with academic and industry groups to develop and provide biomarkers and digital tools to support precision medicine and clinical studies.
Clinical trial collaboration for radiopharmaceutical studies
Support for clinical evaluation of radiodiagnostics and radiotherapeutics, including trial design, operational execution, and clinical validation to inform regulatory filings.
Expertise Areas
- Radiopharmaceutical development
- Radiotheranostics (paired diagnostic and therapeutic agents)
- Clinical trial management for imaging agents and radiotherapeutics
- GMP manufacturing and kit formulation for radiopharmaceuticals
Key Technologies
- Positron emission tomography (PET) radiotracers
- SPECT radiotracers
- Radioisotope labeling (18F, 68Ga, 177Lu, 64Cu, Tc-99m, Xe-133)
- Radioligand therapy (targeted radiotherapeutics)